FR14C0016I1 - - Google Patents

Info

Publication number
FR14C0016I1
FR14C0016I1 FR14C0016C FR14C0016I1 FR 14C0016 I1 FR14C0016 I1 FR 14C0016I1 FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 I1 FR14C0016 I1 FR 14C0016I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR14C0016I1 publication Critical patent/FR14C0016I1/fr
Application granted granted Critical
Publication of FR14C0016I2 publication Critical patent/FR14C0016I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
FR14C0016C 2001-07-27 2014-02-21 WEST NILE VACCINE Active FR14C0016I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (en) 2001-07-27 2002-07-23 West nile vaccine

Publications (2)

Publication Number Publication Date
FR14C0016I1 true FR14C0016I1 (en) 2014-03-28
FR14C0016I2 FR14C0016I2 (en) 2015-07-24

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0016C Active FR14C0016I2 (en) 2001-07-27 2014-02-21 WEST NILE VACCINE

Country Status (25)

Country Link
US (8) US7153513B2 (en)
EP (3) EP1427444B1 (en)
JP (2) JP4718778B2 (en)
KR (2) KR20040028952A (en)
CN (2) CN1273189C (en)
AU (1) AU2002365244B2 (en)
BE (1) BE2014C006I2 (en)
BR (1) BRPI0211492B1 (en)
CA (1) CA2452545C (en)
CY (1) CY2014010I1 (en)
DK (1) DK1427444T3 (en)
ES (1) ES2435095T3 (en)
FR (1) FR14C0016I2 (en)
HK (1) HK1066470A1 (en)
HR (1) HRP20040195B1 (en)
HU (2) HU228690B1 (en)
LU (1) LU92348I2 (en)
ME (1) ME00491B (en)
MX (1) MXPA04000680A (en)
NZ (3) NZ570270A (en)
PL (2) PL220846B1 (en)
PT (1) PT1427444E (en)
RS (1) RS53184B (en)
WO (1) WO2003061555A2 (en)
ZA (1) ZA200401596B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
EP1427444B1 (en) * 2001-07-27 2013-08-21 Zoetis W LLC West nile vaccine
WO2005024427A2 (en) * 2003-09-09 2005-03-17 Idexx Laboratories, Inc. Detection of west nile virus infection and vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (en) 2004-05-17 2009-07-17 Pasteur Institut RECOMBINANT LENTIVIRAL VECTOR FOR EXPRESSION OF FLAVIVIRIDAE PROTEIN AND ITS APPLICATIONS AS VACCINE
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
AU2006232865A1 (en) * 2005-04-01 2006-10-12 Wyeth Use of WNV DNA vaccine in combination with a conventional vaccine to overcome immunogen interference
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
EP1724338A1 (en) * 2005-05-19 2006-11-22 Crucell Holland B.V. Methods for the production of a whole-inactivated West Nile Virus vaccine
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
US8048429B2 (en) 2005-06-24 2011-11-01 Intervet International B.V. Inactivated chimeric flavivirus
BRPI0617735B1 (en) * 2005-10-19 2022-05-17 University Of Florida Research Foundation Inc Compositions comprising isolated viruses, polynucleotides, or polypeptides, expression constructs, vaccines, kits to protect a canine from influenza virus infection, use of the virus in the preparation of a pharmaceutical composition as well as an in vitro method for detecting an influenza virus that is capable of infect a canid animal
EP1941033A2 (en) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions and methods for the treatment of canine influenza virus disease
AU2006338210A1 (en) * 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
DK2395018T3 (en) * 2006-06-06 2016-04-25 Crucell Holland Bv HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof
UA98812C2 (en) 2007-11-06 2012-06-25 Вайет Ллк Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
EP2306812A4 (en) * 2008-07-30 2013-02-20 Univ Kentucky Res Found Equine disease model for herpesvirus neurologic disease and uses thereof
NZ603854A (en) * 2008-08-29 2015-03-27 Boehringer Ingelheim Vetmed West nile virus vaccine
MX2012004133A (en) * 2009-10-07 2012-05-08 Wyeth Llc Compositions comprising adjuvant, macrolide and proteinaceous antigen and methods of use thereof.
US9187730B2 (en) 2011-03-14 2015-11-17 Boehringer Ingelheim Vetmedica, Inc. Equine rhinitis vaccine
CN103045544B (en) * 2011-10-17 2015-01-14 华中农业大学 Recombinant pseudotyped baculovirus Bac-G-prM/E for preventing West Nile virus as well as vaccine and application thereof
CA2911938C (en) * 2013-05-14 2019-07-16 Zoetis Services Llc Vaccine compositions comprising sp oil and p-class immunostimulatory oligonucleotides
AU2014315353A1 (en) * 2013-09-05 2016-03-10 Zoetis Services Llc Hendra and Nipah virus G glycoprotein immunogenic compositions
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
PL70842Y1 (en) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Device for regeneration of solid particles filters and automobile analytic converters
CA3130781A1 (en) 2019-02-27 2020-09-03 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (en) * 1993-03-08 1996-06-07 Rhone Merieux Water-in-oil fluid vaccine emulsions containing a metabolizable oil.
EP0968722B1 (en) * 1994-05-10 2007-06-20 Wyeth Improved modified live BRSV vaccine
US7417136B1 (en) 1998-06-04 2008-08-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU2002211524B2 (en) * 2000-10-04 2007-03-22 The Trustees Of The University Of Pennsylvania Highly expressible genes
WO2002068637A2 (en) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Nucleic acid-based treatment of diseases or conditions related to west nile virus infection
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
AU2002309508A1 (en) * 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (en) * 2001-04-06 2004-02-06 Merial Sas VACCINE AGAINST NILE FEVER VIRUS
EP1427444B1 (en) * 2001-07-27 2013-08-21 Zoetis W LLC West nile vaccine
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens

Also Published As

Publication number Publication date
CY2014010I1 (en) 2020-05-29
EP2281572A1 (en) 2011-02-09
US7153513B2 (en) 2006-12-26
US7648706B2 (en) 2010-01-19
NZ531265A (en) 2008-08-29
PL220846B1 (en) 2016-01-29
HUS1300055I1 (en) 2016-08-29
PL368535A1 (en) 2005-04-04
YU8004A (en) 2006-08-17
HU228690B1 (en) 2013-05-28
EP2283858A2 (en) 2011-02-16
US20030091595A1 (en) 2003-05-15
HRP20040195A2 (en) 2004-08-31
BRPI0211492B1 (en) 2016-06-21
US20070166326A1 (en) 2007-07-19
EP2283858A3 (en) 2011-03-23
KR20090053967A (en) 2009-05-28
HUP0401606A3 (en) 2005-02-28
US20070166325A1 (en) 2007-07-19
JP2011057692A (en) 2011-03-24
CN1935258B (en) 2013-04-03
AU2002365244B2 (en) 2007-12-06
PL398575A1 (en) 2012-06-18
WO2003061555A3 (en) 2004-04-15
US20070231349A1 (en) 2007-10-04
EP1427444A2 (en) 2004-06-16
EP1427444B1 (en) 2013-08-21
MXPA04000680A (en) 2004-04-05
US20070166802A1 (en) 2007-07-19
CN1935258A (en) 2007-03-28
LU92348I2 (en) 2014-09-22
BE2014C006I2 (en) 2021-02-04
US7445787B2 (en) 2008-11-04
BR0211492A (en) 2004-08-17
EP1427444A4 (en) 2008-01-02
US20070231350A1 (en) 2007-10-04
HRP20040195B1 (en) 2014-07-18
ZA200401596B (en) 2005-07-27
KR20040028952A (en) 2004-04-03
US7648705B2 (en) 2010-01-19
NZ570270A (en) 2010-08-27
ME00491B (en) 2011-10-10
ES2435095T3 (en) 2013-12-18
PL212212B1 (en) 2012-08-31
US20070166324A1 (en) 2007-07-19
WO2003061555A2 (en) 2003-07-31
NZ553165A (en) 2008-09-26
DK1427444T3 (en) 2013-11-04
HK1066470A1 (en) 2005-03-24
LU92348I9 (en) 2019-01-02
CA2452545A1 (en) 2003-07-31
RS53184B (en) 2014-06-30
CN1535157A (en) 2004-10-06
FR14C0016I2 (en) 2015-07-24
JP2005515236A (en) 2005-05-26
CN1273189C (en) 2006-09-06
HUP0401606A2 (en) 2004-11-29
CA2452545C (en) 2015-06-09
US20070178119A1 (en) 2007-08-02
JP4718778B2 (en) 2011-07-06
PT1427444E (en) 2013-11-19

Similar Documents

Publication Publication Date Title
BE2022C531I2 (en)
BE2022C502I2 (en)
BE2022C547I2 (en)
BE2017C057I2 (en)
BE2017C051I2 (en)
BE2017C032I2 (en)
BE2016C051I2 (en)
BE2015C046I2 (en)
BE2014C052I2 (en)
BE2014C036I2 (en)
BE2014C026I2 (en)
BE2014C006I2 (en)
BE2017C050I2 (en)
BRPI0209186B1 (en)
JP2001306446A5 (en)
CH1379220H1 (en)
BRPI0204884A2 (en)
BE2016C021I2 (en)
HU0202920D0 (en)
DE60236526D1 (en)
JP2002214561A5 (en)
BRPI0101486B8 (en)
JP2002016647A5 (en)
JP2002222017A5 (en)
JP2001225612A5 (en)